Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Edap TMSFOCL -2.25%56 EV-to-EBITDA is -5.97 as of Aug. 10, 2026. GuruFocus rates FOCL with a GF Score™ of 56/100 and a GF Value™ of $4.45 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 99 Medical Distribution companies, Edap TMS ranks worse than 1010100% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Edap TMS's enterprise value is $240.7 Mil.
Edap TMS's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-40.3 Mil. Therefore, Edap TMS's EV-to-EBITDA for today is -5.97.
The historical rank and industry rank for Edap TMS's EV-to-EBITDA or its related term are showing as below:
FOCL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -905.71 Med: -3.59 Max: 420.25
Current: -5.97
During the past 13 years, the highest EV-to-EBITDA of Edap TMS was 420.25. The lowest was -905.71. And the median was -3.59.
FOCL's EV-to-EBITDA is ranked worse than 100% of 99
companies
in the Medical Distribution industry
Industry Median: 8.68
vs FOCL: -5.97
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Edap TMS's share price for today is $6.08.
Edap TMS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.827.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Edap TMS's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Edap TMS's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edap TMS EV-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Edap TMS's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Edap TMS's EV-to-EBITDA falls into.
Edap TMS's current Enterprise Value is $240.7 Mil.
Edap TMS's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-40.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edap TMS (FOCL) has a EV-to-EBITDA of -5.97 as of Aug. 10, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Edap TMS. According to the industry distribution chart, Edap TMS ranks #999999 out of 99 companies in the Medical Distribution industry.
Is Edap TMS's EV-to-EBITDA too high?
Edap TMS's current EV-to-EBITDA is -5.97. Based on the distribution chart, Edap TMS ranks #999999 out of 99 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Edap TMS has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Edap TMS's EV-to-EBITDA compare to ACH and YI?
According to the Medical Distribution industry distribution chart, Edap TMS ranks #999999 out of 99 companies for EV-to-EBITDA. This places Edap TMS in the lower half of its industry. The industry median EV-to-EBITDA is 8.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Distribution company?
The median EV-to-EBITDA among Medical Distribution companies is 8.68, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Edap TMS. For the Medical Distribution industry, the median EV-to-EBITDA is 8.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edap TMS's current EV-to-EBITDA is -5.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edap TMS stock overvalued right now?
Based on GuruFocus' analysis, Edap TMS (FOCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.45, compared to a current price of $6.08 — trading 36.6% above its estimated fair value. The current EV-to-EBITDA is -5.97. Edap TMS's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Edap TMS (FOCL), the current EV-to-EBITDA is -5.97 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edap TMS (FOCL) Overvalued in 2026?
Based on GuruFocus' analysis, Edap TMS stock appears to be overvalued.
The current stock price of $6.08 is trading 36.6% above its estimated GF Value™ of $4.45.
GuruFocus considers Edap TMS to be Significantly Overvalued.
Key valuation signals for FOCL:
EV-to-EBITDA: -5.97
GF Value™: $4.45 vs. price of $6.08 (36.6% above fair value)
No single metric tells the full story. See the FOCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.
56GF Score
Get the complete analysis for FOCL
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FOCL has been successfully added to your 
